株式会社ジーエヌアイグループ 2023年12月期 第２四半期連結決算概要

This document presents the consolidated financial results for the second quarter of the fiscal year ending December 2023 for GNI Group, Inc. The company achieved a significant increase in revenue, with sales rising by 72.9% year-on-year to 14,096 million yen, and operating profit soaring by 445.1% to 5,476 million yen. Key developments include the profitability of major subsidiaries and a large contract with Astellas Pharma, highlighting advancements in global pharmaceutical development. Notably, sales growth in the U.S. market is remarkable, indicating promising future growth.